Trials / Completed
CompletedNCT04138641
Dutch Cangrelor Registry
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 250 (actual)
- Sponsor
- Isala · Academic / Other
- Sex
- All
- Age
- 18 Years – 110 Years
- Healthy volunteers
- —
Summary
Cangrelor is a fast and directly acting platelet aggregation inhibitor. It is potentially indicated for several types of patients who are undergoing PCI. A nationwide cangrelor registry has up until now not been performed and with the introduction of cangrelor in the Netherlands its efficacy and safety will be determined.
Conditions
- STEMI - ST Elevation Myocardial Infarction
- NSTEMI - Non-ST Segment Elevation MI
- Coronary Artery Disease
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Cangrelor | Cangrelor intravenous |
Timeline
- Start date
- 2019-12-17
- Primary completion
- 2020-07-24
- Completion
- 2020-07-24
- First posted
- 2019-10-24
- Last updated
- 2020-07-28
Locations
1 site across 1 country: Netherlands
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04138641. Inclusion in this directory is not an endorsement.